📊 Score Breakdown
Offering Ability
40
Cash Runway
40
Float Risk
22
Warrant Exposure
15
Convertible Debt—
🌦️ Dilution Forecast
☀️
Clear
No significant dilution signals
9%
💰 Capital Raise
18%
• Active ATM program with $200M remaining capacity
💹 Market Data
Market Cap$3.99B
Shares Outstanding310.98M
Float207.89M
Cash$243.79M
Debt$45.95M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↑ 4.5% shares (2025Q4 vs prior)
154 institutional holders · 228.69M shares
#1
Frazier Life Sciences Management, L.P.
22.73M shares
#2
T. Rowe Price Investment Management, Inc.
20.90M shares
#3
VR ADVISER, LLC
17.86M shares
+ 17 more holders Sign up free to view →
📉 Short Interest
Short Interest31.43M
Days to Cover6.7
% of Float15.1%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL CONVERTIBLE
Dec 31, 2021
4
INSIDER TRANSACTION
Apr 03, 2026
4
INSIDER TRANSACTION
Mar 06, 2026
4
INSIDER TRANSACTION
Jan 30, 2026
4
INSIDER TRANSACTION
Jan 30, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for ERAS
📊 ERAS FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 ERAS Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.